Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) plunged November 8 as Q3 earnings missed estimates and the company reduced its 2016 full-year revenue and profit guidance.

Contrarian investors have been kicking the tires in recent months, thinking all the bad news was already priced into the stock.

Apparently, that isn’t the case.

Earnings

Valeant reported Q3 2016 adjusted earnings per share (EPS) of US$1.55, which was much lower than the US$1.75 per share analysts had expected.

Revenue was pretty much in line with expectations at US$2.48 billion, but the company painted a negative picture for the rest of this year and 2017.

The dermatology business is weak, and the company says any improvements it makes in its restructuring efforts in the near term are likely to be offset by increased competition for its portfolio of generic drugs as well as weakness connected to coming patent expirations in the neurology segment.

Full-year 2016 revenue is now targeted at US$9.55-9.65 billion, which is down from the US$9.9-10.1 billion previously forecast. Adjusted earnings for the year are expected to be just US$5.30-5.50 per share rather than US$6.60-7.00.

Ouch!

The dismal results led to a 25% drop in the stock price at the open, taking the share price below $19. At the time of writing, Valeant recovered some ground, but still traded down 19% at $20.70 per share.

Volatility

The stock’s dramatic fall comes just a week after it rocketed 30% higher on news the company was looking to sell off its Salix business for US$10 billion to help pay down debt.

Traders are having a field day, but contrarian investors–who have been looking at the company’s pipeline and buying on the belief that the stock was simply way oversold–just found out that cheap stocks often get a lot cheaper before they finally recover.

Not that long ago, when the stock first fell to $30 per share, pundits were saying it had definitely bottomed and was a screaming buy.

Should you buy now?

Valeant’s new management team is working hard to right the ship, but it is going to take time. This was confirmed in the Q3 report with CEO Joseph Papa warning 2017 was going to bring more pain.

At some point, this company should recover, and those who manage to pick it up at the bottom are likely to do well. For the moment, however, the risk of getting burned is still too great, and investors should probably look for other opportunities.

Stock buy alert hits astounding 96% success rate!

The hand-picked investing team inside Stock Advisor Canada recently issued a buy alert for one special type of "bread-and-butter" stock where The Motley Fool U.S. has banked profits on 23 out of 24 recommendations. Frankly, with an astounding 96% success rate that has delivered average returns of 260%, chances are this new pick could deliver life-changing returns as well. Because the team at Stock Advisor Canada fully embraces the same time-tested investing philosophies that have led to countless Motley Fool winners globally. So simply click here to unlock the full details behind this new recommendation and join Stock Advisor Canada.

*96% accuracy includes restaurant stock recommendations from Motley Fool U.S. services Stock Advisor, Rule Breakers, Hidden Gems, Income Investor and Inside Value since each services inception. Returns as of 5/27/16.

NEW! This Stock Could Be Like Buying Amazon In 1997

For only the 5th time in over 14 years, Motley Fool co-founder David Gardner just issued a Buy Recommendation on this recent Canadian IPO.

Stock Advisor Canada’s Chief Investment Adviser, Iain Butler, also recommended this company back in March – and it’s already up a whopping 57%!

Enter your email address below to claim your copy of this brand new report, “Breakthrough IPO Receives Rare Endorsement.”

Fool contributor Andrew Walker has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.